A clinical study from Colombia, published in the Indian Journal of Medical Research, the peer-reviewed journal of the Indian Council of Med.
Since its first approval in 2022, Gilead Sciences’ lenacapavir—a twice-yearly injectable—has come to be a potential game ...
Scientists found that nasal cells act as a first line of defense against the common cold, working together to block ...
A new study shows that the body’s early immune response, not the virus itself, often determines how severe a rhinovirus cold ...
Learn how the body’s earliest immune defenses can stop a common cold before symptoms appear.
When a rhinovirus, the most frequent cause of the common cold, infects the lining of our nasal passages, our cells work ...
The Indian Council of Medical Research is fast-tracking an experimental RNA-based antiviral therapy for Chikungunya, inviting ...
Researchers at Yale School of Medicine have used lab-grown human nasal tissue to show that a fast interferon response can ...
Researchers use cryo-EM and optical tweezers to investigate how an antiviral interacts with the herpes simplex virus.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback